Jariyapamornkoon N, Nuanualsuwan S, Suanpairintr N
Animals (Basel). 2024; 14(13).
PMID: 38998027
PMC: 11240368.
DOI: 10.3390/ani14131916.
Jover-Saenz A, Ramirez-Hidalgo M, Belles Belles A, Murillo E, Batlle Bosch M, Cayado Cabanillas J
Antibiotics (Basel). 2022; 11(12).
PMID: 36551433
PMC: 9774161.
DOI: 10.3390/antibiotics11121776.
Bouiller K, Zayet S, Lalloz P, Potron A, Gendrin V, Chirouze C
Antibiotics (Basel). 2022; 11(2).
PMID: 35203801
PMC: 8868337.
DOI: 10.3390/antibiotics11020198.
Cattoir V, Pourbaix A, Magnan M, Chau F, de Lastours V, Felden B
Front Microbiol. 2020; 11:575031.
PMID: 33193186
PMC: 7607045.
DOI: 10.3389/fmicb.2020.575031.
Elliott Z, Barry K, Cox H, Stoesser N, Carroll J, Vegesana K
J Clin Microbiol. 2019; 57(10).
PMID: 31340992
PMC: 6760957.
DOI: 10.1128/JCM.00634-19.
Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis.
Pourbaix A, Guerin F, Burdet C, Massias L, Chau F, Cattoir V
Antimicrob Agents Chemother. 2019; 63(8).
PMID: 31160291
PMC: 6658801.
DOI: 10.1128/AAC.00903-19.
Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.
Gardiner B, Stewardson A, Abbott I, Peleg A
Aust Prescr. 2019; 42(1):14-19.
PMID: 30765904
PMC: 6370609.
DOI: 10.18773/austprescr.2019.002.
Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
Martin-Gutierrez G, Docobo-Perez F, Rodriguez-Beltran J, Rodriguez-Martinez J, Aznar J, Pascual A
Antimicrob Agents Chemother. 2017; 62(1).
PMID: 29038268
PMC: 5740309.
DOI: 10.1128/AAC.01899-17.
Mutations of the Transporter Proteins GlpT and UhpT Confer Fosfomycin Resistance in .
Xu S, Fu Z, Zhou Y, Liu Y, Xu X, Wang M
Front Microbiol. 2017; 8:914.
PMID: 28579984
PMC: 5437707.
DOI: 10.3389/fmicb.2017.00914.
Fosfomycin: Mechanism and Resistance.
Silver L
Cold Spring Harb Perspect Med. 2017; 7(2).
PMID: 28062557
PMC: 5287057.
DOI: 10.1101/cshperspect.a025262.
Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis.
Zhanel G, Walkty A, Karlowsky J
Can J Infect Dis Med Microbiol. 2016; 2016:2082693.
PMID: 27366158
PMC: 4904571.
DOI: 10.1155/2016/2082693.
Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.
Poeppl W, Lingscheid T, Bernitzky D, Schwarze U, Donath O, Perkmann T
Antimicrob Agents Chemother. 2014; 58(9):5111-6.
PMID: 24936591
PMC: 4135863.
DOI: 10.1128/AAC.02720-13.
Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.
Keating G
Drugs. 2013; 73(17):1951-66.
PMID: 24202878
DOI: 10.1007/s40265-013-0143-y.
Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake.
Kurabayashi K, Hirakawa Y, Tanimoto K, Tomita H, Hirakawa H
J Bacteriol. 2013; 196(2):248-56.
PMID: 24163343
PMC: 3911262.
DOI: 10.1128/JB.01151-13.
Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.
Oliva A, Furustrand Tafin U, Maiolo E, Jeddari S, Betrisey B, Trampuz A
Antimicrob Agents Chemother. 2013; 58(3):1284-93.
PMID: 24145537
PMC: 3957906.
DOI: 10.1128/AAC.02583-12.
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.
Couce A, Briales A, Rodriguez-Rojas A, Costas C, Pascual A, Blazquez J
Antimicrob Agents Chemother. 2012; 56(5):2767-9.
PMID: 22371901
PMC: 3346583.
DOI: 10.1128/AAC.06122-11.
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Lagler H
Antimicrob Agents Chemother. 2011; 55(11):4999-5003.
PMID: 21859942
PMC: 3194995.
DOI: 10.1128/AAC.00584-11.
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.
Lu C, Liu C, Huang Y, Liao C, Teng L, Turnidge J
Antimicrob Agents Chemother. 2011; 55(9):4295-301.
PMID: 21670185
PMC: 3165352.
DOI: 10.1128/AAC.00349-11.
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Poeppl W, Tobudic S, Lingscheid T, Plasenzotti R, Kozakowski N, Georgopoulos A
Antimicrob Agents Chemother. 2010; 55(2):931-3.
PMID: 21098253
PMC: 3028784.
DOI: 10.1128/AAC.00881-10.
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.
Rodriguez-Rojas A, Macia M, Couce A, Gomez C, Castaneda-Garcia A, Oliver A
PLoS One. 2010; 5(4):e10193.
PMID: 20419114
PMC: 2855370.
DOI: 10.1371/journal.pone.0010193.